ÂÜÀòÂÒÂ×

Dr. Nader N. Youssef is SVP, Global Medical Affairs and Patient Partnership at VectivBio. He is a board-certified pediatric gastroenterologist with specialized training in neurogastroenterology focused on intestinal motility and failure disorders.

Most recently, Dr. Youssef served as vice president of clinical development at Passage Bio. Prior to that, he was a chief medical officer at Nutrinia where he helped secure more than $31M in financing, secured orphan drug designation for a lead product candidate, and completed a pivotal phase III trial in premature infants with intestinal malabsorption. Previously he was executive director of GI global clinical development and medical affairs for NPS Pharmaceuticals (acquired by the Shire in 2015) which included responsibility for the overall regulatory and development strategy of teduglutide. During his time there, the team secured marketing approval and supported the initial launch for teduglutide in the U.S. (Gattex®) and Europe (Revestive®) for the treatment of adult and pediatric short bowel syndrome. He has held key roles in development at AstraZeneca and was a chief medical officer at Electrocore in the past.

Dr. Youssef received a B.S. in finance and international business from New York University Stern School of Business. He earned his M.D. from Ross University School of Medicine and an MBA from the University of Pittsburgh Katz School of Business. His residency was completed at Robert Wood Johnson University Hospital and his fellowship at the Children’s Hospital of Pittsburgh. He has been published in many high-impact journals including Gastroenterology and Pediatrics.